|
AEZS Cosciens Biopharma Inc 1113423 |
| Income Statement |
|
Revenue
|
form6-k
|
1,871,000 |
|
Net Income
|
form6-k
|
-5,755,000 |
|
Profit Margin
|
|
-307.59% |
| Balance Sheet |
|
Current Assets
|
28,221,000 |
|
Assets
|
43,769,000 |
|
Current Liabilities
|
8,167,000 |
|
Liabilities
|
43,769,000 |
| Cash Flow Statement |
|
Operating Cash Flow
|
-7,779,000 |
|
Investing Cash Flow
|
83,000 |
| Market Analysis |
|
BVPS
|
558.25 |
|
PB
|
0.02 |
|
PS
|
0.10 |
|
FCF
|
-7,696,000 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view AEZS documents filed with the SEC.
AEZS Filings
Clear
